Member Info for elrico

Bazza,

With respect, investing should always focus on the future. While I acknowledge that the placing dilutes our shares once again (when will it end?), it is, on the surface, surprising given the assurance that SBTX was funded through Q1 with a £500k buffer if needed. This suggests a cautious approach, anticipating potential delays from Croda based on their history. I doubt there will be a delay because the clinical study is the end of the line. It's about price point royalties. For all we know, Croda is already forward selling, as they suggested was the plan.

Premier Miton is a strong institution to have on board, possibly the best among SBTX's current investors. The additional funds also put SBTX in a much better bargaining position should Croda want to expand the commercial agreement beyond cosmetics. Have you considered this?

SA is a much better CEO than you, or Mr Angry give him credit for. I suspect you will soon be seeking a discount of your own from OPTI to help you cope with all the humble pie you will be chucking down your neck.

Please refrain from accusing the board of dishonesty due to a lack of understanding of the processes involved or the relevant time periods, which may be clearer to some observers. There are stringent regulations that limit what can be disclosed. We were provided with minimal information, but there were hints during the IMC, including at the beginning if you were attentive.

The discounts being mentioned are inaccurate. I will investigate further once Ashman returns from his holiday.

In my opinion, we should focus on the future. It is evident that SBTX is currently in a very strong position.

https://open.substack.com/pub/lemminginvestor/p/skinbiotherapeutics-plc-e6a?r=kcv2o&utm_campaign=post&utm_medium=web

https://lemminginvestor.substack.com/

This is just another reason why Dermatonics just had to be done ASAP. It is looking more astute bit of business as time ticks along and another layer is peeled back.

Parsons, on the guild thread on AD V

Ref Sederma's cosmetic clients. All we know for sure is that Matrixl is an active ingredient in over 90% of skin care cosmetics. We also have a rather glaring clue about a high-street brand, which I would wager is one of the two names SA said they were in discussions with for the Axis pillar: Boots.

RNS October 2023

Croda's Consumer Care division, which includes Sederma, has the largest active ingredients portfolio in the industry across over 15,000 customer/product combinations. The Group's strategy is to drive its market leadership by adding innovative technologies and reinforcing the substantiation of its ingredient claims.

Sederma is part of Croda's Beauty Active's business unit and is a specialist in bioactive ingredients for the cosmetic industry. According to Croda's HY results to 30 June 2023, the Group reported that Sederma's premium active ingredients business grew by over 30% through a mix of geographical expansion and the launch of new customer products e.g. the new Boots no7 Future Renew range.

End

Matrixl

Industry benchmark: Matrixyl is often used to evaluate the anti-wrinkle capabilities of other anti-ageing active ingredients, suggesting it has become a standard in the industry.

Global presence: Almost 4,000 cosmetic products worldwide trust genuine Matrixyl in their formulas.

It won't happen overnight, but I expect our lysate, whatever branding it is used to market, will take over as the new benchmark. This may sound a flippant, if not ridiculous uber bullish/ramp comment at this stage. If this is anyone thinking, ask yourself why Croda/Sederma have invested in time, money, and resources these past five years.

Both SBTX and Croda have a very exciting conversation ahead. I doubt it will be several years down the road either.

Https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-708/comments

Hi Bigpunt,

It's a 500k facility, a buffer if they need it. It gives the Company breathing space while it waits for Croda royalties to drop.

Highlights:

Dr Chahal's appointment is significant given what lies ahead with Croda

No funding issues with the £500k facility if required

Two big high street retailers for AxisBiotix discussion ongoing

Croda royalties by YE

Croda forecast around October

Hints of other near-term projects that will bring in revenues

2nd acquisition boosts revenues to £6m + EBITDA around £1.8m without Croda or other income.

https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-708

Hi Bigpunt, My sincere apologies. I'm way too keen to engage in a bit of banter.

We seem aligned in our thoughts. That is refreshing.

Once again, sorry for being a pratt.

I am not one for "I told you so," but I'll make an exception. I told you so. Macquaries short has reduced. I wonder what this could mean? A hedge, Sir?

Big mouth, I don’t have a PhD. I do have masters in something that need explaining to me. Hope this helps.

I’ve no problem with anyone explaining I’m wrong. More power to them as it helps us all. Petty teen snipes are not. However, if helps you grow and inch I applaud you, good sir!

I’ve explained this. We will soon see why IMHO.

Ref to my previous posts on this topic. It’s not a full fat short, it’s a hedge Macquarie has used several times. Don’t allow yourself to be spooked by other posts conspiracies.

SBTX will never see 5p. It is clear to the observer with eyes can see the SP is being held in a damn tight range after the collapse brought about by the first £500k conversion. I suspect this was Macquarie's strategy, allowing to convert each month at around current levels subject to the VWAP. Since then, the SP has been remarkably stable. There's a clue in there.

More on the Dermatonics/UMG and potential commercial routes. https://lemminginvestor.substack.com/p/skinbiotherapeutics-plc-fb4

IMHO, UMG qualifies as a multinational. If you have read my comments on Substack, you will have noted that I have identified multiple commercial partnerships within UMG. The collaboration with Dermatonics, in particular, should be viewed through the lens of SBTX. The potential here is immense; frankly, I am surprised there hasn't been more discussion around UMG's potential, especially given that it is a stated intention and not merely hypothetical speculation on my part. I would have expected TW to offer some insights on the matter, yet he has remained silent. Quite baffling!

Hi Farris,

In the order, I would like as a wish...

1: The clearance of CB is a significant step forward. Although it has been a considerable hurdle, it is evident that the potential upside far outweighs the downside. Some may still anticipate lower SP, but the tight trading range is instructive for attentive investors. If the CBs are not entirely cleared by the 29th, I remain optimistic since at least two-thirds, if not more, have already been converted and washed through the market. If the short last week provided the same result as the £500k we could see a TR1 next week. I won't hold my breath because I don't trust Macquarie.

2: It is crucial that we see revenue growth from Dermatonics, AxisBiotix, and, to a lesser extent, UMG. There is no evidence of Once Heel Balm market availability, and despite the March launch, the training for the 1,200-strong sales team has neither been completed; otherwise, the product(s) would be visible. Increased revenues should extend the cash runway beyond April/May, by which time we expect to see contributions from Croda revenues. Confirmation of this would put a sock in a particular fog horn for a while longer.

3: It would be immensely beneficial if Croda could confirm forward sales of the premium version of the lysate to their VIP clients. Given the market's competitive nature, this may only become clear after summer. The developments with some of the most iconic brands will be particularly intriguing to watch.

4: UMG and Croda forecasts remain uncertain at this stage, especially considering the ongoing training requirements for UMG, which may not yet be complete. Updates on the clinical study (Lysate) are also unlikely in light of the points above. But I can wish.

5: New commercial routes with UMG - Perhaps AxisBiotix pillar via their commercial footprint.

6: Acne commercial progress/Launch

I could go on, but there is less significance in doing so.

Baz,

If I said it’s being managed (manipulated- your language) it has the appearance of a purpose. IMHO, you’ll witness a huge bounce once the shackles have been removed. That will be a sure sign the CBs have been cleared. A strategy is being played out, that I am certain of. Get the hoover out while you can. 🍺

Spot on Mark. Exactly the same process for the £500k conversion, which resulted in a short open and closed within days. Macquarie seem to be hedging.

#OPTI broker PeterHouse argues via its note today, ‘SweetBiotix (sugar alternative), which it is planning to launch this year and already has agreements in place with CocaCola, Nestle, and a host of other partners.’ https://lemminginvestor.substack.com

https://x.com/LEMMINGINVESTOR/status/1814326644674384296

I beg to differ. Once the M&A activity is complete, I'd judge Manprit on the quality rather than make assumptions based on his reduced salary. From my discussion with Manprit and Ashman, he is not just a garden-variety CFO beancounter. The CB clouds the judgment, but I truly believe all will be vindicated, and large slices of humble pie will be on the menu.